Kevin church athira
Web31 jan. 2024 · “Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET … Web31 jan. 2024 · BOTHELL, Wash., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on …
Kevin church athira
Did you know?
WebFounder of Blueripple Capital LLC, Kelly A. Romano currently occupies the position of Co-Chairman at Potter Electric Signal Co. LLC, Chairman for Athira Pharma, Inc., Chief Executive Officer for... Web7 mrt. 2024 · Kevin entered a career in the life sciences industry in 2006, and has served as the Executive Vice President of Research at Athira since November 2024. Following …
Web31 jan. 2024 · Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer Published: Jan 31, 2024 BOTHELL, Wash., Jan. 31, 2024 (GLOBE … WebSummary. Kevin Church is Executive Vice President-Research at Athira Pharma, Inc. Dr. Church received a doctorate from Washington State University and an undergraduate …
Web31 jan. 2024 · Dr. Church joined Athira in 2016 and most recently served as Executive Vice President, Research. In his current role, he leads the discovery and preclinical … WebKevin Church is Executive Vice President-Research at Athira Pharma, Inc. Dr. Church received a doctorate from Washington State University and an undergraduate degree …
Web23 jan. 2024 · ATHA Athira Pharma, Inc. Kevin Church. Executive VP and Research. Option: 3,152: $1.04: $3,278. 8 Jun 2024 44,133: ↗ Athira Pharma executives and stock …
WebBOTHELL, Wash., Dec. 21, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and … tried and true chocolate chip cookie recipesWeb11 apr. 2024 · Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma Date/Time: Monday, April 24, at 2:24 p.m. EDT. Title: Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer’s Disease terrell county board of educationWebAthira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND. ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS. tried and true consignment store